Date: 2016-03-17
Type of information: Nomination
Compound:
Company: GSK (UK)
Therapeutic area:
Type agreement: nomination
Action mechanism:
Disease:
Details: * On March 17, 2016, GSK announced that Sir Deryck Maughan, Dr Stephanie Burns, Dr Daniel Podolsky and Hans Wijers will not stand for re-election to the Board at GSK’s Annual General Meeting on 5 May 2016. Sir Deryck has served as Independent Non-Executive Director on the Board since 2004, and from 2013, as the Senior Independent Director. He is a member of the Audit & Risk, Nominations and Remuneration Committees. Dr Podolsky has served as Independent Non-Executive Director and Scientific & Medical Expert for nine years and is a member of the Audit & Risk and Corporate Responsibility Committees. Hans Wijers will also not stand for re-election at the AGM following the completion of a three year term on the Board as Independent Non-Executive Director. Mr Wijers is a member of the Corporate Responsibility and Remuneration Committees. Professor Sir Roy Anderson and Dr Jesse Goodman have been appointed members of the Corporate Responsibility Committee with effect from 1 May 2016. With effect from the end of the Company’s AGM on 5 May 2016, the composition of the Board of GSK will be as follows: Sir Philip Hampton, Non-Executive Chairman
Sir Andrew Witty, Chief Executive Officer
Mr Simon Dingemans, Chief Financial Officer
Dr Moncef Slaoui, Chairman, Global Vaccines
Professor Sir Roy Anderson, Independent Non-Executive Director
Mr Vindi Banga, Senior Independent Non-Executive Director
Ms Stacey Cartwright, Independent Non-Executive Director
Ms Lynn Elsenhans, Independent Non-Executive Director
Dr Jesse Goodman, Independent Non-Executive Director
Ms Judy Lewent, Independent Non-Executive Director
Mr Urs Rohner, Independent Non-Executive Director
Financial terms:
Latest news:
